Anti-Human PDGF-AA (Clone 114506)

Purified Recombinant Human PDGF-AA (Accession # P04085)

This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 7.2 - 7.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.

The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human PDGF-AA bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human PDGF-AA (at 25 ng/ml) is 0.2 - 1.0 µg/ml.

Mouse Anti-Human Platelet-Derived Growth Factor AA (PDGF-AA) (Clone 114506) recognizes an epitope on Human PDGF-AA. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype. This antibody shows approximately 20% cross-reactivity with rhPDGF-AB and no cross-reactivity with rhPDGF-BB, rhPlGF, rhVEGF206, rhVEGF B186, rhVEGF C, rhVEGF D, or rhCTGF.

Platelet-derived growth factor (PDGF), an agent with important mitogenic effects for bone cells, exists in three isoforms, PDGF-AA, - BB, and –AB.¹ The A-chain homodimers of the platelet-derived growth factor (PDGF AA) are widely expressed in normal and transformed cells.² PDGF AA is a potent mitogen for a wide range of cell types including fibroblast, smooth muscle, and connective tissue. PDGF-AA and its receptor represent an important epithelial-mesenchymal interaction which plays a critical role in early lung branching morphogenesis.³ PDGF AA is also an essential autocrine regulator for vascular endothelial growth factor (VEGF) expression. It regulates the frequency and level of VEGF expression during the transition from a precancerous lesion to advanced cancer.⁴

1. Canalis, E. et al. (1994) Endocrin. 134: 2541
2. Deuel, TF. et al. (1992) Biochem Biophys Res Commun. 186: 1510
3. Post, M. et al. (1995) Endocrin. 121: 25529
4. Sueishi, K. et al. (2005) Cancer Research 65: 7241